Title

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.

Authors

Jacqueline C Barrientos
Peter Hillmen
Gilles Salles
Jeff Sharman
Stephan Stilgenbauer
Oksana Gurtovaya
Guan Xing
Bianca Ruzicka
Pankaj Bhargava
Paolo Ghia
John M Pagel, Swedish Cancer Institute, Seattle, WA, USAFollow

Document Type

Article

Publication Date

12-10-2020

Publication Title

Leukemia & lymphoma

Keywords

Hemorrhage; PI3K inhibitor; anticoagulant; antiplatelet; thrombocytopenia

Abstract

The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This

Clinical Institute

Cancer

Department

Oncology

Recommended Citation

Barrientos, Jacqueline C; Hillmen, Peter; Salles, Gilles; Sharman, Jeff; Stilgenbauer, Stephan; Gurtovaya, Oksana; Xing, Guan; Ruzicka, Bianca; Bhargava, Pankaj; Ghia, Paolo; and Pagel, John M, "No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib." (2020). Articles, Abstracts, and Reports. 4259.
https://digitalcommons.providence.org/publications/4259